Elypta key facts
- Developer a metabolism-based liquid biopsy platform designed to prevent cancer mortality through earlier detection and closer monitoring.
- It has raised $29.8M; the latest was Accelerator/Incubator in Oct 2024.
- Notable investors include Chalmers Ventures, Industrifonden, Norrsken VC, The Roddenberry Foundation, 3T Invest — 17 tracked in total.
- Status: Privately Held (backing).
Who backs Elypta
17+- ·The complete investor list: 17 names
- ·Watch Elypta: the Monday email on marks, rounds and moves
Elypta funding rounds
No funding rounds for Elypta are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Elypta investors
17 investors are on record for Elypta, including Chalmers Ventures, Industrifonden, Norrsken VC and The Roddenberry Foundation.
About Elypta
Developer a metabolism-based liquid biopsy platform designed to prevent cancer mortality through earlier detection and closer monitoring. The company's platform utilizes assay technology for comprehensive profiling of glycosaminoglycan metabolites as well as scoring software for the broad potential across cancer indications with applications ranging from screening to response monitoring, enabling physicians to detect early-stage cancer when symptoms are inconclusive.
- Sector
- Healthcare
- HQ
- Solna, Sweden
- Founded
- 2017
- Employees
- 30
- Website
- elypta.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Elypta doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.